Literature DB >> 24293392

MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.

Li-Hong Wang1, Xu Wang, Wen-Ting Xu, Ya-Li Hu.   

Abstract

Case-control studies on the association between mouse double minute 2 homolog (MDM2) rs2279744 polymorphism and endometrial cancer have provided either controversial or inconclusive results. To clarify the effect of MDM2 rs2279744 polymorphism on the risk of endometrial cancer, a meta-analysis of all case-control observational studies was performed. Pooled odds ratios (ORs) for various polymorphisms were estimated using random and fixed effect models. Q-statistic was used to evaluate the homogeneity, and Egger and Begg tests were used to assess publication bias. Overall, the MDM2 rs2279744 polymorphism was associated with a risk of endometrial cancer (OR = 0.76; 95% CI = 0.64-0.90 for allele contrast, p = 0.002, P(het) = 0.003). The contrast of homozygotes and the recessive and dominant models produced the same pattern of results as the allele contrast. In the analysis stratified by ethnicity, significant associations were found in the Caucasian population in all of the genetic models. Our pooled data suggest evidence for a major role of MDM2 rs2279744 polymorphism in the carcinogenesis of endometrial cancer, especially among Caucasian populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293392     DOI: 10.1007/s13277-013-1413-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

Review 1.  MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.

Authors:  Yan Li; Hongjin Zhao; Li Sun; Linjuan Huang; Qifeng Yang; Beihua Kong
Journal:  Hum Cell       Date:  2011-03-04       Impact factor: 4.174

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.

Authors:  Stian Knappskog; Jone Trovik; Janusz Marcickiewicz; Solveig Tingulstad; Annetine C Staff; Pål Romundstad; Kristian Hveem; Lars Vatten; Helga B Salvesen; Per E Lønning
Journal:  Eur J Cancer       Date:  2011-11-24       Impact factor: 9.162

4.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

5.  Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Authors:  Christine S Walsh; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Journal:  Gynecol Oncol       Date:  2006-11-21       Impact factor: 5.482

6.  Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.

Authors:  Agnieszka Zając; Grzegorz Stachowiak; Tomasz Pertyński; Hanna Romanowicz; Jacek Wilczyński; Beata Smolarz
Journal:  Pol J Pathol       Date:  2012-12       Impact factor: 1.072

7.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

8.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Authors:  Masatsugu Ueda; Michiko Yamamoto; Osamu Nunobiki; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-05       Impact factor: 4.174

9.  Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Mark McEvoy; John Attia; Michael Gilbert; Ute Hamann; Rodney J Scott
Journal:  Gynecol Oncol       Date:  2009-02-03       Impact factor: 5.482

10.  Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Authors:  Tomoko Yoneda; Ayumi Kuboyama; Kiyoko Kato; Tatsuhiro Ohgami; Kanako Okamoto; Toshiaki Saito; Norio Wake
Journal:  Oncol Rep       Date:  2013-04-29       Impact factor: 3.906

View more
  3 in total

1.  The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells.

Authors:  Yajian Duan; Gaoen Ma; Xionggao Huang; Patricia A D'Amore; Feng Zhang; Hetian Lei
Journal:  J Biol Chem       Date:  2016-05-31       Impact factor: 5.157

2.  Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility.

Authors:  Qixin Cao; Yun Wang; Xiaohui Song; Weihua Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

3.  Association between genetic polymorphisms and endometrial cancer risk: a systematic review.

Authors:  Cemsel Bafligil; Deborah J Thompson; Artitaya Lophatananon; Miriam J Smith; Neil Aj Ryan; Anie Naqvi; D Gareth Evans; Emma J Crosbie
Journal:  J Med Genet       Date:  2020-02-17       Impact factor: 6.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.